Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Abeona Therapeutics (NQ: ABEO )

6.250 -0.160 (-2.50%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Abeona Therapeutics

< Previous 1 2 3 4 5 Next >
Why Is Greenwave Technology Solutions (GWAV) Stock Down 47% Today?
Greenwave Technology Solutions stock is down on Tuesday as GWAV investors react to a registered direct offering and private placement. 
Via InvestorPlace
Why Is Abeona Therapeutics (ABEO) Stock Down 45% Today?
Abeona Therapeutics stock is falling on Tuesday after the FDA sent it a CRL for more CMC data before it would approve Pz-cel. 
Via InvestorPlace
Exposures Product Safety
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why Hibbett Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Recap: Abeona Therapeutics Q3 Earnings
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
We're diving into the biggest pre-market stock movers that traders are going to want to keep an eye on for Tuesday morning! 
Via InvestorPlace
Calix Reports Mixed Results, Joins Cadence Design Systems And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Abeona Therapeutics Provides Regulatory Update on Pz-cel
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
ABEO Stock Earnings: Abeona Therapeutics Misses EPS for Q4 2023
ABEO stock results show that Abeona Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Abeona Therapeutics Reports Full Year 2023 Financial Results and Announces Completion of FDA Inspections
- FDA completed Pre-License Inspection of Abeona’s Cleveland manufacturing facility, as well as inspection of clinical trial sites for pz-cel pivotal Phase 3 VIITAL™ study - 
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Processa Pharmaceuticals And 2 Other Penny Stocks Insiders Are Buying
The Dow Jones index closed higher by around 150 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics Announces Progress Update on Pz-cel Biologics License Application (BLA)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics Announces $50 Million Credit Facility
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Abeona Therapeutics Announces FDA Accepts and Grants Priority Review for Pz-cel Biologics License Application (BLA)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Developments
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
The 7 Most Undervalued Penny Stocks to Buy in October 2023
Undervalued penny stocks offer tremendous return for investors with an appetite for risk but these shares are relatively safe as well. 
Via InvestorPlace
Abeona Therapeutics Submits Biologics License Application to U.S. FDA Seeking Priority Review and Approval of EB-101 for the Treatment of Patients with Recessive Dystrophic Epidermolysis Bullosa
From Abeona Therapeutics Inc.
Via GlobeNewswire
3 Biotech Blockbusters to Turn $5,000 Into $50,000
These transformative early-stage biotech stocks can deliver triple-digit upside if their key milestones are achieved on time. 
Via InvestorPlace
Abeona Therapeutics Appoints Madhav Vasanthavada, Ph.D., M.B.A. as Chief Commercial Officer
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics Announces Participation in Upcoming Investor Conferences
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics Announces Positive Pre-BLA Meeting with FDA for EB-101 and Plans for BLA Submission
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics Reports Second Quarter 2023 Financial Results
From Abeona Therapeutics Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.